Yahoo · Aug 14, 2026
Form 8.3
LONDON, August 14, 2026-- FORM 8.3
PH
NASDAQ · PHAR
Pharming Group N.V.
Healthcare · Biotechnology
$11.21
Up+$0.41 (+3.75%)
Updated Sep 12, 2026, 11:25 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.2B
- P/E ratio
- 3,147.1
- Dividend yield
- 0.00%
- 52-week range
- $9.62 – $18.41
- Volume
- 39.07K
- Avg. volume
- 16.7K
Price performance
PHAR price history
1M range · 20 trading sessions · Daily adjusted prices
PHAR closed at $11.21 after 20 trading sessions, down 4.35% for the selected period.
- Last close
- $11.21
- Period change
- -4.35%
- Period low
- $10.81
- Period high
- $11.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $10.82 | $11.693 | $10.6516 | $11.21 | 39.07K |
| Sep 10, 2026 | $10.91 | $10.9695 | $10.67 | $10.805 | 15.34K |
| Sep 9, 2026 | $11.15 | $11.54 | $10.97 | $10.97 | 12.13K |
| Sep 8, 2026 | $11.38 | $11.50 | $11.30 | $11.50 | 21.51K |
| Sep 4, 2026 | $11.16 | $11.54 | $11.16 | $11.23 | 5.54K |
| Sep 3, 2026 | $11.38 | $11.48 | $11.305 | $11.46 | 5.35K |
| Sep 2, 2026 | $11.5118 | $11.5506 | $11.20 | $11.20 | 4.99K |
| Sep 1, 2026 | $11.36 | $11.59 | $11.0292 | $11.11 | 34.51K |
| Aug 31, 2026 | $11.50 | $11.66 | $11.48 | $11.48 | 12.36K |
| Aug 28, 2026 | $11.81 | $11.81 | $11.6284 | $11.70 | 9.45K |
| Aug 27, 2026 | $11.835 | $11.96 | $11.7701 | $11.78 | 6.43K |
| Aug 26, 2026 | $11.86 | $12.32 | $11.72 | $11.95 | 35.54K |
| Aug 25, 2026 | $11.67 | $11.96 | $11.67 | $11.77 | 21.51K |
| Aug 24, 2026 | $11.62 | $12.21 | $11.4501 | $11.46 | 23.17K |
| Aug 21, 2026 | $11.76 | $11.97 | $11.73 | $11.85 | 11.01K |
| Aug 20, 2026 | $11.84 | $12.0335 | $11.68 | $11.68 | 17.98K |
| Aug 19, 2026 | $11.89 | $12.05 | $11.675 | $11.85 | 17.23K |
| Aug 18, 2026 | $11.65 | $11.91 | $11.50 | $11.91 | 22.01K |
| Aug 17, 2026 | $11.72 | $12.1215 | $11.72 | $11.79 | 17.28K |
| Aug 14, 2026 | $11.92 | $12.5083 | $11.6672 | $11.72 | 20.71K |
Latest PHAR news
The latest Smart Investors Daily articles mentioning PHAR.
Stock researchCompany · Overview
PHAR research
Overview
Company profile and research snapshot.
Company profile
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $42.00
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 12, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| May 7, 2026 | OPPENHEIMER & CO., INC. | Outperform | — |
| Mar 29, 2026 | JEFFERIES | Buy | — |
| Feb 25, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Feb 4, 2026 | OPPENHEIMER & CO., INC. | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 13, 2026
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan Leiden, the Netherlands, August 13, 2026: Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with activated PI3K delta syndrome (APDS) aged 4 years and older, following it
Benzinga · Aug 13, 2026
Pharming Launches Joenja (Leniolisib) in Japan for APDS Patients Aged 4 and Older, Marking First Global Launch for Children 4 To 11
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwideOrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan
Yahoo · Aug 4, 2026
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan, VP Investor Relations and Capital Markets, will participate in a Fireside Chat Q&A session on Wednesday, August 12 at 10:00 EDT/16:00 CEST. For more information about the conference, or to schedule a one-on-one meeting with Pharming’s management team, please
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
